Tuesday, 9 September 2008

Levocetirizine tablets (Xyzal tablets, 5mg): Perrigo acquire rights from first para IV filer Synthon

Generic manufacturer Perrigo has acquired the exclusive U.S. rights to sell and distribute Levocetirizine tablets, the generic version of innovator UCB’s Xyzal tablets (5mg), from Synthon Pharma. Synthon was first to file ANDA application with Para IV certification against only orange book listed patent US5698558 (Expiry: September 24, 2012, which covers method of use of levocetrizine), and can get 180 days of exclusivity upon approval and successful litigation. Synthon and innovator UCB are currently engaged in Paragraph IV/Hatch-Waxman litigation over the Synthon ANDA filing.
Earlier, innovator has filed lawsuit against Synthon, Sun Pharmaceuticals, Sandoz and Barr
Earlier news of IPPharmadoc on Xyzal litigation Here

Posted by ADKS at 10:22 am

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)
web page statistics
Disclaimer: "IP Pharma Doc" blog is published for information purpose only. "IP Pharma Doc" blog contains no legal advice. I assume no legal responsibility for the views/information expressed here. “IP Pharma Doc” blog is my personal website and not edited by my employer, accordingly, no part of my blog should be attributed to my employer. All information on the present blog should be double checked for its accuracy and applicability. © Dr. Sarwal (2007)
 
eXTReMe Tracker